|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 3.060 USD | -3.77% |
|
+10.67% | +60.21% |
Company Valuation: C4 Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,566 | 288.8 | 278.4 | 254.1 | 185.1 | 376.5 | - | - |
| Change | - | -81.55% | -3.6% | -8.73% | -27.16% | 103.37% | - | - |
| Enterprise Value (EV) 1 | 1,500 | 21.89 | 24.76 | 9.216 | 185.1 | 295.2 | 259.3 | 247.8 |
| Change | - | -98.54% | 13.11% | -62.77% | 1,908.48% | 59.46% | -12.15% | -4.42% |
| P/E | -17.7x | -2.25x | -2.12x | -2.37x | -1.5x | -3.6x | -3.24x | -2.77x |
| PBR | 4.02x | 1x | 1.39x | 1.18x | - | 1.92x | 1.82x | 2.16x |
| PEG | - | -0.1x | -1.11x | 0.1x | 0.1x | 0.1x | -0.3x | -0.2x |
| Capitalization / Revenue | 34.2x | 9.29x | 13.4x | 7.14x | 5.15x | 14.3x | 16.9x | 18.1x |
| EV / Revenue | 32.8x | 0.7x | 1.19x | 0.26x | 5.15x | 11.2x | 11.6x | 11.9x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -18.3x | -0.17x | -0.18x | -0.08x | -1.61x | -2.35x | -1.61x | -1.24x |
| EV / FCF | -17x | -0.2x | -0.23x | -0.14x | -1.86x | -2.95x | -2.23x | -1.69x |
| FCF Yield | -5.88% | -509% | -438% | -709% | -53.6% | -33.9% | -44.9% | -59.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.82 | -2.62 | -2.67 | -1.52 | -1.27 | -0.8508 | -0.9437 | -1.104 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 45.78 | 31.1 | 20.76 | 35.58 | 35.95 | 26.4 | 22.29 | 20.79 |
| EBITDA | -59.13 | -97.84 | -109.9 | -85.7 | - | - | - | - |
| EBIT 1 | -82.13 | -129.5 | -139 | -117.2 | -115.2 | -125.5 | -160.9 | -200.6 |
| Net income 1 | -83.89 | -128.2 | -132.5 | -105.3 | -105 | -113.1 | -145.9 | -184.5 |
| Net Debt 1 | -65.36 | -267 | -253.7 | -244.9 | - | -81.29 | -117.2 | -128.6 |
| Reference price 2 | 32.200 | 5.900 | 5.650 | 3.600 | 1.910 | 3.060 | 3.060 | 3.060 |
| Nbr of stocks (in thousands) | 48,626 | 48,957 | 49,281 | 70,589 | 96,914 | 123,025 | - | - |
| Announcement Date | 2/24/22 | 2/23/23 | 2/22/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.6x | 11.18x | - | - | 376M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| Average | 23.73x | 24.93x | 15.68x | 0.32% | 38.35B | |
| Weighted average by Cap. | 26.69x | 25.31x | 15.90x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CCCC Stock
- Valuation C4 Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
